The prognostic value of phosphatase and tensin homolog negativity in breast cancer: A systematic review and meta-analysis of 32 studies with 4393 patients
Publication in refereed journal


Times Cited
Web of Science6WOS source URL (as at 30/07/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractThe prognostic value of phosphatase and tensin homolog (PTEN) negativity in breast cancer has been evaluated by many studies but remains controversial. We conducted a meta-analysis to assess the association of PTEN negativity with overall survival and disease-free survival. Thirty-two studies with 4393 patients were identified. PTEN negativity was significantly associated with unfavorable overall survival in breast cancer (hazard ratio = 1.89, 95% confidence interval 1.58-2.26), with low heterogeneity among the studies (I-2 = 25%, P = 0.160) and no evidence for publication bias. Meta-analysis of multivariate hazard ratios and sensitivity analyses did not materially change the results. The data on disease-free survival was heterogeneous (I-2 = 61.9%, P<0.001), with a summary hazard ratio of 1.57 (95% confidence interval 1.31-1.89). The exact source of heterogeneity remains unclear. We thus concluded that PTEN negativity was significantly associated with unfavorable prognosis in terms of overall survival in breast cancer. (C) 2016 Published by Elsevier Ireland Ltd.
All Author(s) ListYang ZY, Yu YY, Yuan JQ, Shen WX, Zheng DY, Chen JZ, Mao C, Tang JL
Journal nameCritical Reviews in Oncology/Hematology
Year2016
Month5
Day1
Volume Number101
PublisherELSEVIER SCIENCE INC
Pages40 - 49
ISSN1040-8428
eISSN1879-0461
LanguagesEnglish-United Kingdom
Keywordsbreast cancer; disease-free survival; meta-analysis; overall survival; phosphatase and tensin homolog; prognosis; systematic review
Web of Science Subject CategoriesHematology; Oncology

Last updated on 2020-31-07 at 02:25